Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miptenalimab - Boehringer Ingelheim

Next Previous
Drug Profile

Miptenalimab - Boehringer Ingelheim

Alternative Names: BI-754111

Latest Information Update: 31 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • No development reported Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 03 Dec 2024 Boehringer Ingelheim completes a phase-II trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, Canada, and the UK (IV) (NCT03697304),
  • 03 Jul 2023 Miptenalimab is still in phase I development for Solid tumours in Spain, USA, Canada, Poland and United Kingdom (IV) (NCT03156114)
  • 06 Jun 2023 Boehringer Ingelheim completes a phase I trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA, Canada, Poland, Spain and United Kingdom (Parenteral) (NCT03156114)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top